TABLE 1.

Demographic and clinical characteristics of individual patients.

Patient number	Age (years)	Height (cm)	Weight (kg)	Lymphoma histology and Ann Arbor stage	Chemotherapy scheme and frequency of application	Additional systemic therapy	Vincristine cumulative dose (mg/m2)
1	59	183	66.0	DLBCL Stage IV A	R‐CHOP every 3 weeks	Rituximab (twice)	3.78
2	55	170	115.0	DLBCL Stage II A	R‐CHOP every 3 weeks	None	2.71
3	51	179	83.0	FBCL Stage I A	R‐CHOP every 2 weeks	None	2.97
4	58	158	59.0	PTCL Stage II AE	CHOP every 3 weeks	None	5.03
5	71	180	85.0	DLBCL Stage IV B	R‐CHOP every 3 weeks	None	2.93
6	39	178	90.7	DLBCL Stage IV B	R‐CHOP every 3 weeks	None	2.93
7	44	182	85.0	LBCL Stage IV A	R‐CHOP every 4 weeks	None	6.76
8	71	183	106.0	DLBCL Stage I A	R‐CHOP every 4 weeks	None	5.36
9	43	181	90.0	DLBCL Stage II A	R‐CHOP every 3 weeks	None	3.79
10	69	184	95.0	DLBCL Stage III A	R‐CHOP every 3 weeks	None	2.74
11	55	163	67.0	DLBCL Stage I BE	R‐CHOP every 3 weeks	None	3.50
12	60	184	104.5	DLBCL Stage I A	R‐CHOP every 3 weeks	None	2.63
Median (patients) [IQR]	56.5 [21.00]	180.5 [11.0]	87.5 [31.13]	n.a.	n.a.	n.a.	3.3 [1.93]
Median (controls) [IQR]	49.5 [14.50], p = .163	172.5 [16.0], p = .203	81.8 [23.25], p = .198	n.a.	n.a.	n.a.	n.a.

Abbreviations: CHOP, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone; DLBCL, diffuse large B‐cell lymphoma; FBCL, follicular B‐cell lymphoma; IQR, interquartile range; LBCL, large B‐cell lymphoma; n.a., not applicable; PTCL, peripheral T‐cell lymphoma; R‐CHOP, CHOP + Rituximab.